title: Kick-starting the cancer-immunity cycle by targeting CD40.
abstract: Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.
authors.affiliation: Alligator Bioscience AB ; Lund, Sweden ; Department of Immunotechnology; Lund University ; Lund, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Ellmark
authors.affiliation: Department of Immunology, Genetics and Pathology; Uppsala University ; Uppsala, Sweden.
authors.forename: S M
authors.initials: SM
authors.lastname: Mangsbo
authors.affiliation: Alligator Bioscience AB ; Lund, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Furebring
authors.affiliation: Department of Immunology, Genetics and Pathology; Uppsala University ; Uppsala, Sweden.
authors.forename: T H
authors.initials: TH
authors.lastname: Tötterman
authors.affiliation: Alligator Bioscience AB ; Lund, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Norlén
keywords:  CD40; PD-1; agonistic antibody; immunooncology